Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obervation Letter
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Special Article
Specialty Interface
Studies
Study Letter
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Tables
Technology
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
View Point
Viewpoint
What’s new in Dermatology
View/Download PDF
Editorial
2012:78:2;129-132
doi: 10.4103/0378-6323.93626
PMID: 22421640

Update on cutaneous lupus erythematosus

Laxmisha Chandrashekar
 Department of Dermatology and STD, Jawaharlal Nehru Institute of Post Graduate Medical Education and Research, Pondicherry, India

Correspondence Address:
Laxmisha Chandrashekar
Department of Dermatology and STD, JIPMER, Pondicherry 605 006
India
How to cite this article:
Chandrashekar L. Update on cutaneous lupus erythematosus. Indian J Dermatol Venereol Leprol 2012;78:129-132
Copyright: (C)2012 Indian Journal of Dermatology, Venereology, and Leprology

The skin is the second most frequently involved organ in lupus erythematosus (LE). Although cutaneous involvement is rarely life threatening, it is associated with major morbidity. [1] Cutaneous lupus erythematosus (CLE) can be associated with systemic lupus erythematosus (SLE), can precede SLE, or occur on its own. Central to the pathogenesis is loss of immune tolerance and upregulation of the interferon-α (IFN-α) signaling. The clinical spectrum of CLE is wide and includes both specific and nonspecific lesions. These have varying pathologies ranging from primary interface involvement, dermal involvement, or involvement of the subcutis. Disease burden has been quantified by many tools. Cutaneous lupus area severity index (CLASI) is a validated tool for CLE which has been used in numerous studies. The mainstay of treatment is photoprotection, antimalarials, corticosteroids, and calcineurin inhibitors. [1] Indeed, with the advances made in CLE, it is difficult to keep abreast of the latest advances. This article attempts to highlight the recent updates in the field in the past year.

Pathogenesis

Patients with subacute cutaneous lupus erythematosus (SCLE) and discoid lupus erythematosus (DLE) were found to have elevated IFN scores as compared to healthy controls regardless of concomitant SLE. This was found to correlate with the CLASI score. It has also been seen that active CLE is associated with a systemic type I IFN effect that appears to induce a shift toward a Th1-associated chemokine receptor profile. [2] Upregulation of the IFN-inducible antiviral protein Myxovirus A (MxA) in CLE has also been found. This expression was mainly seen in the epidermis and the upper dermis in DLE and SCLE, while in rare cases of lupus tumidus and lupus profundus, MxA was mainly detected in perivascular and subcutaneous areas, respectively, reflecting the distribution of the inflammatory infiltrate in different subsets of CLE. [3] Recently, various cytokines have been found to be involved in CLE. Interleukin (IL)-18 and the overexpression of IL-18 receptor in keratinocytes was found to induce the apoptosis of keratinocytes via increased tumor necrosis factor (TNF)-α and decreased IL-12 production. [4] This apoptotic death was reported to be due to the strong expression of TNF-related apoptosis-inducing ligand (TRAIL) in the skin and the blood of patients with CLE. [5] Some CLE lesions showed increased levels of IL-17, but the precise role of IL-17 is uncertain [4] Moreover, transforming growth factor (TGF)-β serum levels were found to be significantly lower in patients with DLE as compared to the levels in patients with psoriasis and in healthy controls. This downregulation of TGF-β and IL-10 in DLE may lead to defective immune suppression and thus to the generation of the tissue injury that is found in lupus patients. [6] It has been seen that patients with CLE have a low prevalence of skin infections. Kreuter et al. [7] reported that human β-defensin (hBD) 2 and 3, cathelicidin LL-37, and psoriasin were significantly more highly expressed in CLE as compared with healthy controls.

Clinical Features

Patients with active discoid lupus rarely have progressive renal insufficiency. The development of discoid lupus may involve an immunologic mechanism that differs from that which produces severe organ involvement. [8] Overlap of toxic epidermal necrolysis (TEN) and LE is very difficult to diagnose and manage. Ziemer et al. [9] studied patients with TEN like LE. Acute cutaneous manifestations of SLE and Stevens Johnson syndrome (SJS)/TEN can be phenotypically similar. A combination of recent SLE exacerbation, photo-distribution, annular lesions, and absent or only mild focal erosive mucosal involvement may favor LE over SJS/TEN clinically. Histopathologically, junctional vacuolar alteration, presence of solitary necrotic keratinocytes at lower epidermal levels combined with moderate to dense periadnexal and perivascular lymphocytic infiltrates with variable presence of melanophages and mucin point at an LE-related origin.

Some authors feel that Rowell′s syndrome does not qualify as a separate entity. Antiga et al. [10] in their report suggested that LE with erythema multiforme (EM)-like rashes represents a subset of SCLE with targetoid lesions rather than a distinct entity. A real association between DLE and EM was present only in a minority of cases (about 20 patients) and could be considered a mere coincidence without any immunopathological implication or unusual characteristic to either illness. Another big challenge is to differentiate drug-induced SCLE from idiopathic SCLE. Marzano et al. [11] reported that drug induced-SCLE differs from idiopathic SCLE by virtue of distinctive cutaneous features, particularly the widespread presentation and the frequent occurrence of malar rash and bullous, EM-like, and vasculitic manifestations.

There were multiple reports of interesting clinical presentations like linear CLE, [12] linear sclerodermoid LE, [13] comedonal DLE, [14] nonbullous neutrophilic LE, [15] neutrophilic dermatosis in conjunction with LE, [16] and CLE of the elbows. [17]

The clinical presentations of nonbullous neutrophilic LE included urticarial papules, plaques, and subcutaneous nodules. Histopathological findings in all patients included an interstitial and perivascular neutrophilic infiltrate with leukocytoclasia, and variable vacuolar alteration along the dermo-epidermal junction.

Cutaneous Lupus Erythematosus and Cancer

In a Swedish national cohort study which compared 3663 patients diagnosed with CLE in Sweden with a control cohort without CLE, a fourfold increase in risk was seen for buccal cancer, lymphomas, respiratory cancer, and non-melanoma skin cancers. This increase remained when excluding patients also diagnosed with SLE. The authors stressed the importance of non-smoking and sun avoidance and specialized monitoring among these patients. [18]

Outcome Measures

CLASI can be used to classify patients into groups according to disease severity and to identify clinically significant improvements in disease activity. [19] It has also been seen that quality of life in CLE was severely impaired, particularly with respect to emotional well-being. Patients with CLE have worse quality of life than those with other common dermatologic conditions such as acne, nonmelanoma skin cancer, and alopecia. Factors related to poor quality of life include female gender, generalized disease, severe disease, distribution of lesions, and younger age. [20]

Therapy

Topical calcineurin inhibitors were found to be efficacious either as monotherapy or in combination with hydroxychloroquine. Tacrolimus 0.1% was found to be efficacious in a randomized, double-blind, vehicle-controlled trial of 30 patients of CLE, especially in acute, edematous, non-hyperkeratotic lesions of CLE patients. [21]

Wahie et al., [22] in their multicenter observational and pharmacology study, investigated the effects of disease attributes and metabolizing cytochrome P450 (CYP) polymorphisms on clinical outcome of DLE. Although the majority of patients responded to hydroxychloroquine, a significant proportion (39%) either failed to respond or were intolerant to the drug. Cigarette smoking and CYP genotype did not have any significant influence on the response to hydroxychloroquine. Moreover, multivariate analysis indicated that disseminated disease and concomitant SLE were significantly associated with lack of response to hydroxychloroquine. Antimalarials were found to be efficacious in a study of 11 cases of reticular erythematosus mucinosis. It has also been reported that current smokers with LE had worse disease, worse quality of life, and were more often treated with a combination of hydroxychloroquine and quinacrine than were nonsmokers. [23]

Low-dose thalidomide (100 mg daily) was found to effective in a study of 60 consecutive cases of refractory CLE. Complete response occurred in 50 patients (85%). Clinical relapse was frequent (70%) and usually occurred 5 months after withdrawal or reduction of thalidomide. Whereas DLE forms tended to relapse and required a long-term maintenance dose of thalidomide, SCLE forms showed a sustained remission after withdrawal. [24] In a small, open label study of five cases, the authors reported that lenalidomide may have usefulness as therapy for severe, treatment-refractory CLE However, their preliminary data also suggest that lenalidomide may activate T cells and trigger systemic disease in some patients with CLE. [25]

The combination of methotrexate (MTX) and cyclosporine (CsA) might offer a good treatment strategy with potentially additive effects for the durable control of recalcitrant CLE, including SCLE. After an initial phase of combined standard immunosuppressive doses (3 mg/kg/d CsA, 22.5-30 mg MTX per week) the dosage of both agents could be reduced to a maintenance level and no significant side effects were observed in a report of two cases. [26]

Mycophenolate mofetil was also found to be efficacious in the treatment of refractory cutaneous lupus. The mean treatment time to initial response was found to be 2.76 months. The average final dose was 2750 mg/day. [27] Ustekinumab has been used in one case of SCLE. The dramatic and sustained clinical improvement after ustekinumab therapy suggested that either TH1 or TH17 differentiation pathways play a central role in the pathogenesis of SCLE. [28]

Lasers

Pulse dye laser [29] and long pulse Nd:YAG laser [30] were found to be effective in LE tumidus and refractory DLE in two reports. Active features of the lupus lesions responded better as compared to atrophic changes. The selective destruction of cutaneous microvasculature, which may modulate the inflammatory network, leading to regression of DLE lesions, was thought to be the main mechanism of action.

References
1.
Obermoser G, Sontheimer RD, Zelger B. Overview of common, rare and atypical manifestations of cutaneous lupus erythematosus and histopathological correlates. Lupus 2010;19:1050-70.
[Google Scholar]
2.
Braunstein I, Klein R, Okawa J, Werth VP. The IFN-regulated gene signature is elevated in SCLE and DLE and correlates with CLASI score. Br J Dermatol 2012. [In press]
[Google Scholar]
3.
Karageorgas TP, Tseronis DD, Mavragani CP. Activation of type I interferon pathway in systemic lupus erythematosus: Association with distinct clinical phenotypes. J Biomed Biotechnol 2011;2011:273907.
[Google Scholar]
4.
Mikita N, Ikeda T, Ishiguro M, Furukawa F. Recent advances in cytokines in cutaneous and systemic lupus erythematosus. J Dermatol 2011;38:839-49.
[Google Scholar]
5.
Zahn S, Rehkämper C, Ferring-Schmitt S, Bieber T, Tüting T, Wenzel J. Interferon-á stimulates TRAIL expression in human keratinocytes and peripheral blood mononuclear cells: Implications for the pathogenesis of cutaneous lupus erythematosus. Br J Dermatol 2011;165:1118-23.
[Google Scholar]
6.
Antiga E, Del Bianco E, Difonzo E, Fabbri P, Caproni M. Serum levels of the regulatory cytokines transforming growth factor-β and interleukin-10 are reduced in patients with discoid lupus erythematosus. Lupus 2011;20:556-60.
[Google Scholar]
7.
Kreuter A, Jaouhar M, Skrygan M, Tigges C, Stücker M, Altmeyer P, et al. Expression of antimicrobial peptides in different subtypes of cutaneous lupus erythematosus. J Am Acad Dermatol 2011;65:125-33.
[Google Scholar]
8.
Merola JF, Chang CA, Sanchez MR, Prystowsky SD. Is chronic cutaneous discoid lupus protective against severe renal disease in patients with systemic lupus erythematosus? J Drugs Dermatol 2011;10:1413-20.
[Google Scholar]
9.
Ziemer M, Kardaun SH, Liss Y, Mockenhaupt M. Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: A descriptive study of 17 cases from a national registry and review of the literature. Br J Dermatol 2011. [In press]
[Google Scholar]
10.
Antiga E, Caproni M, Bonciani D, Bonciolini V, Fabbri P. The last word on the so-called "Rowell's syndrome"? Lupus 2011. [In press]
[Google Scholar]
11.
Marzano AV, Lazzari R, Polloni I, Crosti C, Fabbri P, Cugno M. Drug-induced subacute cutaneous lupus erythematosus: Evidence for differences from its idiopathic counterpart. Br J Dermatol 2011;165:335-41.
[Google Scholar]
12.
Kim J, Lee SH, Roh MR. Linear cutaneous lupus erythematosus on the midline of the face. J Dermatol 2011;38:609-12.
[Google Scholar]
13.
Khelifa E, Masouye I, Pham HC, Parmentier L, Borradori L. Linear sclerodermic lupus erythematosus, a distinct variant of linear morphea and chronic cutaneous lupus erythematous. Int J Dermatol 2011;50:1491-5.
[Google Scholar]
14.
Farias DF, Gondim RM, Redighieri IP, Muller H, Petri V. Comedonic lupus: A rare presentation of discoid lupus erythematosus. An Bras Dermatol 2011;86:89-91.
[Google Scholar]
15.
Brinster NK, Nunley J, Pariser R, Horvath B. Nonbullous neutrophilic lupus erythematosus: A newly recognized variant of cutaneous lupus erythematosus. J Am Acad Dermatol 2012;66:92-7.
[Google Scholar]
16.
Pavlidakey P, Mills O, Bradley S, Casey J, Morgan MB. Neutrophilic dermatosis revisited: An initial presentation of lupus? J Am Acad Dermatol 2011. [In press].
[Google Scholar]
17.
Bielsa I, Guinovart R, Fernández-Figueras M, Rodríguez C, Ferrándiz C. Cutaneous lupus erythematosus on the elbows: A peculiar localization. Lupus 2012;21:84-8.
[Google Scholar]
18.
Grönhagen CM, Fored CM, Granath F, Nyberg F. Increased risk of cancer among 3,663 patients with cutaneous lupus erythematosus- A Swedish nationwide cohort study. Br J Dermatol 2011. [In press]
[Google Scholar]
19.
Klein R, Moghadam-Kia S, LoMonico J, Okawa J, Coley C, Taylor L, et al. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch Dermatol 2011;147:203-8.
[Google Scholar]
20.
Klein R, Moghadam-Kia S, Taylor L, Coley C, Okawa J, LoMonico J, et al. Quality of life in cutaneous lupus erythematosus. J Am Acad Dermatol 2011;64:849-58.
[Google Scholar]
21.
Avgerinou G, Papafragkaki DK, Nasiopoulou A, Arapaki A, Katsambas A, Stavropoulos PG. Effectiveness of topical calcineurin inhibitors as monotherapy or in combination with hydroxychloroquine in cutaneous lupus erythematosus. J Eur Acad Dermatol Venereol 2011. [In press]
[Google Scholar]
22.
Wahie S, Daly AK, Cordell HJ, Goodfield MJ, Jones SK, Lovell CR, et al. Clinical and pharmacogenetic influences on response to hydroxychloroquine in discoid lupus erythematosus: A retrospective cohort study. J Invest Dermatol 2011;131:1981-6.
[Google Scholar]
23.
Piette EW, Foering KP, Chang AY, Okawa J, Ten Have TR, Feng R, et al. Impact of smoking in cutaneous lupus erythematosus. Arch Dermatol 2011. [In press]
[Google Scholar]
24.
Cortés-Hernández J, Torres-Salido M, Castro-Marrero J, Vilardell-Tarres M, Ordi-Ros J. Thalidomide in the treatment of refractory cutaneous lupus erythematosus: Prognostic factors of clinical outcome. Br J Dermatol 2011. [In press]
[Google Scholar]
25.
Braunstein I, Goodman NG, Rosenbach M, Okawa J, Shah A, Krathen M, et al. Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: Histologic and circulating leukocyte profile and potential risk of a systemic lupus flare. J Am Acad Dermatol 2011.
[Google Scholar]
26.
Klein A, Vogt T, Wenzel SM, Fleck M, Landthaler M. Cyclosporin combined with methotrexate in two patients with recalcitrant subacute cutaneous lupus erythematosus. Australas J Dermatol 2011;52:43-7.
[Google Scholar]
27.
Gammon B, Hansen C, Costner MI. A comment on mycophenolate mofetil and hydroxychloroquine: An effective treatment for recalcitrant cutaneous lupus erythematosus. J Am Acad Dermatol 2012;66:161-2.
[Google Scholar]
28.
De Souza A, Ali-Shaw T, Strober BE, Franks AG Jr. Successful treatment of subacute lupus erythematosus with ustekinumab. Arch Dermatol 2011;147:896-8.
[Google Scholar]
29.
Truchuelo MT, Boixeda P, Alcántara J, Moreno C, de Las Heras E, Olasolo PJ. Pulsed dye laser as an excellent choice of treatment for lupus tumidus: A prospective study. J Eur Acad Dermatol Venereol 2011. [In press]
[Google Scholar]
30.
Park KY, Lee JW, Li K, Seo SJ, Hong CK. Treatment of refractory discoid lupus erythematosus using 1,064-nm long-pulse neodymium-doped yttrium aluminum garnet laser. Dermatol Surg 2011;37:1055-6.
[Google Scholar]

Fulltext Views
622

PDF downloads
220
Show Sections